The development process for apomorphine SL as an effective treatment for patients with erectile dysfunction has been somewhat unusual. As often is the case, much of the impetus for the basic research originated in academia. However, somewhat unusually, the impetus for early stage clinical research also lay in the hands of the academics. This article represents a historical perspective from one of those involved throughout.
Introduction
One of the riskiest propositions in industry is the development of a new drug for human use. Although the benefits to consumers and to the manufacturer can be exceedingly large, the path from the pre-clinical studies (mostly in vitro and animal research) to the drug store is fraught with difficulties. These may well include initially encouraging but later irreproducible experimental results, unforeseeable developments, and idiosyncratic reactions and, above all, lack of efficacy or an unacceptable safety profile. Only rarely does a molecule follow a straight and easy pattern of development; the vast majority require substantial structural modifications and make a voyage involving a variety of twists and turns before even reaching a phase I trial (to establish clinical human safety). Additional surprises appear during the efficacy evaluation (phase II trial) when the anticipated effectiveness of the molecule fails to materialize or it is associated with excessive undesirable effects. The moment of truth, however, occurs during controlled randomized trials (phase III studies) that normally require a large number of patients from different sites and compares the performance of the new compound with either a placebo or other available therapies. It is not uncommon for a new drug and its handlers to take more than 10 y in travelling this route. Of course, hundreds of others travel the route but fall by the side of road at different steps. Some do so very early, others quite late, just within sight of the promised land of the regulatory agencies.
In the field of erectile dysfunction (ED) one cannot think of a better example of this difficult and unrewarding route than the events surrounding RS153385 later named delequamine by its developer, Syntex Laboratories. After the initial controlled clinical studies had shown that alpha adrenoceptor blockade with yohimbine resulted in modest but probably significant sexual responses, 1 interest arose in producing more specific ('cleaner') alpha blocking agents. Delequamine was investigated with this purpose in mind. Animal experiments showed the drug to be effective and initial studies in human volunteers documented its safety. Limited phase II studies 2 convinced the manufacturers that delequamine had commercial potential and multicenter, international clinical trials were initiated. Finally, a larger company acquired Syntex Laboratories. The new owners assessed the data and the decision was made to withdraw further development of the drug. The causes were never clearly explained to the investigators. Several years of work and millions of dollars were simply abandoned. This molecule was developed as a selective alpha-2 adrenergic blocking agent. It is possible that, as discussed later, it may have clinical value in combination with a different class of drugs. At present, however, its' fate is in limbo.
Apomorphine made this perilous journey from different beginnings but in no shorter span of time. Apō , as we have come to call the developing phenomenon, has weathered the development process well despite the major turbulence of Viagra. None of the upheaval to come or the timeliness was visible from the vantage point of a specialty that needed a benign remedy over a decade ago. Nor was it immediately apparent that diversity in mechanism would mark this product, although it was obvious that the brain was the center of the sexual world. The following sketch brings together some of the accepted elements of apō 's progress.
The development process
Maytom et al, 3 nicely summarized the phases of pharmaceutical drug development. Briefly, it starts with the idea for a new compound, its' chemical development and the short-term animal studies (the discovery phase). This is followed by an initial review of results, long-term animal studies, toxicology studies, investigational new drug (IND) submission and phase I and II clinical trials (development phase). Upon accumulation and analysis of this large amount of information (including phase III trials) about the drug in humans, it enters the approval phase where the gathered data is submitted to regulatory agencies. If the compound passes this final hurdle, it will enter the commercialization phase. Apomorphine, in its original formulation did not go through the initial steps (eg idea for a new compound and chemical development) of the discovery phase but it made its' pilgrimage through all the others.
Apomorphine
Although opium and its' medical uses were well known by the 3rd century BC, 4 apomorphine, as a chemical compound, was not developed until the 19th century. It was first prepared by Mathiesson et al 5 and its' structure finally determined very early in the 20th century. Following its' development, some of the effects of apomorphine in the central nervous system of the dog were promptly established. 6 In humans it was employed in the management of psychiatric disorders due to its' sedative effect -determined empirically. It was eventually recognized that in suitable doses it acted as a centrally acting emetic by directly stimulating the medullary chemoreceptor trigger zone (CTZ). 7 In the 1960s the central effects of apomorphine as a dopaminergic agonist became recognized. Because it represented a prototypical and accessible dopaminergic compound increasing interest in it developed. 8 
Chemistry
Apomorphine was initially prepared simply by acid treatment of morphine. 5 In this process, a molecule of water is eliminated and a molecular re-arrangement takes place. The two molecules (morphine and apomorphine) look quite different with apomorphine having marked structural similarity to the endogenous neurotransmitter, dopamine ( Figure 1 ). In addition, apomorphine has much less 3-dimensional depth than morphine, exhibits totally unrelated pharmacological actions and has no interaction at opiate receptors. Apomorphine is easily oxidized but remains stable for long periods when stored in the presence of an antioxidant. 8 Degradation products and metabolites lack biological activity.
Pharmacology
Soon after it was developed, 5 apomorphine was recognized to have a wide range of pharmacological actions. At first, emetic, antimanic and antispasmodic activities were reported although application as a sedative in psychiatric disorders dominated its use in the first half of the 20th century. The identification in the 1960s and 70s that apomorphine's central nervous system (CNS) effects are associated primarily with actions and structural similarity of a dopaminergic agonist, 9 coincided with the widespread recognition of the importance of dopaminergic function in many aspects of CNS function. These developments lead a wave of investigative activity, in particular, involving apomorphine as a prototypical centrally acting dopaminergic agonist. 10 Apomorphine was found to have a rapid CNS onset of action and a short half-life (15 -90 min depending on route of administration) even after peripheral administration. The disposition of apomorphine is now well known to involve an ability to rapidly traverse oral, nasal and intestinal mucosa, as well as the blood-brain barrier due to its lipophilicity, such that many routes of administration (subcutaneous, sub-lingual (SL), nasal and rectal) have been used in clinical practice. The transrectal route Apomorphine to Uprima 1 may not be effective and the oral route results in diminished bioavailability because of strong firstpass liver metabolism. 11 The volume of distribution of apomorphine is 1 -2 times body weight although this characteristic masks its' selective distribution ie the real clinical effect of apomorphine is causally linked to its' concentration in the brain tissue and cerebrospinal fluid. It is widely acknowledged that peripheral action of apomorphine is limited by the extensive hepatic metabolism with only 3 -4% of the molecule being excreted unchanged. Assessment of the relationship between time to onset, duration of effect and pharmacokinetic parameters such as C max and T max has revealed substantial discordance depending on the route of administration. That is, the CNS-initiated onset and duration of effect clearly does not always correlate with its' pharmacokinetic profile in the peripheral circulation. This points to at least two factors: the first that the distribution of apomorphine follows a multi-compartment model; the second is that differential effects also probably derive from the usual variances in receptor density and function according to site. Accordingly, opportunistic development of formulations using existing routes of delivery could thereby optimize the delivery of apomorphine to the site of action in the CNS at the appropriate concentration for specific desired effects. This, of course, is a crucial point for the developments described below. The clinical profile achieved is unique to the formulation of apomorphine SL that has been developed and approved by the regulatory authorities. The modeling of the clinical profile of apomorphine SL based on pharmacokinetics, distribution into different tissue compartments, pharmacological selectivity for dopamine receptor subtypes, the known physiology of dopamine and the new clinical evidence is shown in Figure 2 . As can be seen in retrospect, it is possible to explain that for apomorphine SL it could be possible to create a clear separation between the pro-erectile effects and the side effects.
Early application of apomorphine as an erectogenic drug

Experimental
The efficacy of apomorphine as a compound capable of producing penile erections in rodents was first reported by Banassi-Benelli. 12 The behavioral changes and the genital response were easy to observe, once the pattern had been recognized. The importance of this erectile response in the study of general erectile physiology was recognized and resulted in the development of a model in which apomorphine induced erections in rodents was characterized by Heaton et al. 13 In a series of elegant and well documented experiments it was shown that rats respond reliably to apomorphine with a picture characterized by genital grooming, yawning and penile erections shortly after its sub-cutaneous (s.c.) administration. This 'bio-assay' allowed a number of interventions mimicking clinical situations (ie cavernosal injury, hypogonadism) that, while affecting the erectile response, preserved the yawning and grooming. These observations were the first indication that the complex behavioral response had components, each with a slightly different basis, and held out some hope that the erectile response could be teased apart from the other facets of the clinical profile of apomorphine. The obvious advantage of such a model is that the diverse responses provide more than one marker of the drug action separated from the genital response. The model was used successfully later on to study the effect of diabetes and ageing. 14 
Clinical
The erectogenic capabilities of apomorphine were serendipitously observed during the treatment of alcoholics by Schlatter and Lal 15 and subsequently in normal men. 16 Three early studies, conducted in the late 1970s, documented the induction of penile erections in impotent men following the s.c. injection of the compound. 17 -19 These clinical trials, involving a small number of patients, promulgated four main messages: (a) administration of apomorphine (and probably other suitable dopaminergic agonists) results in penile erectile responses in some men with erectile failure, mostly of a psychogenic aetiology (at the time a standard diagnostic label); (b) apomorphine may be valuable as a diagnostic test supplementing or replacing nocturnal penile tumescence monitoring; (c) apomorphine lacks significant therapeutic value because of the induction of nausea and vomiting as limiting factors when sufficient drug is given for an adequate penile response, the
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Apomorphine to Uprima 1 obvious corollary being (d) a dopaminergic agonist devoid of the adverse effects of apomorphine would offer significant possibilities in the treatment of ED. The challenge, therefore, was to find 'other dopaminergic drugs for the treatment of ED.' 17 Based on the concept of opportunistic developments for preferential bioavailability to individual organs of interest, derived in part from understanding the significance of rodent responses, the group at Queen's University saw a therapeutic potential using the old drug by modifying the delivery system to produce a radically different clinical pharmacokinetic and pharmacodynamic clinical profile. The thinking at the time was that the problem was not so much in the drug itself but the route of administration and the speed at which the drug reaches the target centers in the CNS. The careful use of a well-established and fundamentally safe compound -one with wellcharacterized, difficult but not dangerous, side effects -presented some advantages over starting a hunt for a new chemical entity with selected, but clinically unproven, attributes.
The development phase of apomorphine as an oral drug
Up to this point, the apomorphine for animal studies was readily available. This was not the case for the raw material for human use. Our ability to initiate ethically approved human studies depended on the acquisition of raw, hospital grade apomorphine in powder form that would allow the assessment of different vehicles and routes of administration. Early in 1992 we obtained hospital grade apomorphine in a quantity sufficient to initiate clinical investigations. The early human studies explored the possibility of oral administration as a starting point. Very soon it was realized that the bioavailability characteristics via this route of administration, frequently resulted in nausea and vomiting, which proved difficult to control. The intra-nasal (by spray) route also proved not to be ideal without extensive delivery adjustments, due to the rapid absorption of the drug through the mucosa with results similar to the oral route, and the additional drawback of poor patient acceptability. Assessment of a lollipop-like applicator for buccal administration was considered amongst other alternatives. However, this would have potentially resulted in significant salivation, swallowing of the medication and adverse effects similar to those experienced when the direct oral route was used and correspondingly it was dismissed as a viable alternative. The Queen's research team developed the testable hypothesis that a SL approach could be manipulated to deliver the novel profile of drug availability that appeared to be necessary to achieve the desired effects without the burden of adverse effects. From then on, all efforts were focused on the SL route. As our understanding matured, the concept evolved that it was important to have a formulation that allowed fast enough absorption of apomorphine by the oral mucosa to reach therapeutic (erectile) levels within a short period of time. It was equally mandatory that the absorption should be attenuated sufficiently to avoid the undesirable side effects (ie nausea and vomiting). The initial SL formulation was made of apomorphine powder dissolved in a solution of sodium metabisulfite and ethylenediaminetetracetic acid (EDTA) at a final concentration of 100 mg=ml. A preliminary study with progressive doses of liquid apomorphine administered under the tongue was carried out and a gel formulation was tried. This met with only partial success but gave important clues on future formulation developments and clinical trials design. Early in 1992, the study was performed under strict laboratory conditions and with visual sexual stimulation (alternating with neutral segments) and RigiScan recordings. Twelve subjects participated in this limited study. Two men withdrew (one for adverse effects). Of the remaining ten evaluable subjects, seven experienced satisfactory erections and went into a domestic trial of apo at the selected dose. Three of these men required the use of domperidone prior to apo usage to prevent the nausea.
Subsequent studies employed tablets manufactured by Pentech (Wheeling, Illinois). This included a more focused study in which patients were tested on three different occasions with either placebo, 2.5 or 5 mg of apomorphine. As the tablets used in this study resulted in a significant amount of adverse events, a new and different formulation of SL was developed in conjunction with Pentech. In this formulation, although apomorphine remained the only active ingredient, additional proprietary constituents were added to modify the absorption rate with the intent of achieving a bioavaliability profile resulting in efficacious erectogenic activity but without gastro-intestinal adverse effects. The SL tablets used in, what turned out to be the pivotal study, contained 3, 4 and 5 mg of apomorphine. Of the twelve participating patients, eight (67%) experienced excellent responses with both the 3 and 4 mg doses. Most striking, however, was the complete lack of adverse effects with the 3 and 4 mg doses, except for occasional episodes of yawning. The results of this limited but carefully controlled trial were first presented at the biannual meeting of the International Society for Impotence Research in Singapore in 1994 20 and subsequently published as the first methodical evaluation of the SL formulation of apomorphine. 21 The approval phase After the demonstration of the efficacy, safety and good benefit risk ratio of apomorphine as an erectogenic drug, further development became the joint responsibility of Parteq (the technology transfer office of Queen's University) and Pentech. Patent applications were filed in several jurisdictions in 1994 and eventually, the United States Patent Office issued patent No. 5,985,889 on 16 November 1999. Phase II trials were completed, full regulatory clinical and pre-clinical programs were established and large, multicenter studies were carried out under the full leadership of a major multinational pharmaceutical company (TAP Holdings, Wheeling, Illinois). These and subsequent trials by involved companies have confirmed the efficacy and safety of the SL preparation of apomorphine. 22 -24 Many phase III trials have been completed. The results reaffirm the excellent tolerability and efficacy that were the stimulus to put this program into high gear all those years ago. An example of some pertinent efficacy outcomes is shown in Figure 3 . On the basis of the large amount of information accrued from these trials, the drug entered the approval phase. Also the time was ripe for a change of image so the old apomorphine, with new attributes and a specific route of administration, became the new Uprima SL 1 (Abbott International).
The information available from a number of very large phase III clinical trials clearly demonstrated the erectogenic properties of Uprima 1 and its' excellent safety profile at the recommended doses of 2 and 3 mg. The approval process in Europe was successfully completed in January 2001 when the European Committee for Proprietary and Medicinal Products (CPMP) granted approval for Uprima 1 . The process for approval is progressing in other regions.
Phase IV studies
Despite the large number of men receiving the drug and the voluminous amount of information gathered, safety and efficacy evaluations normally continue for years. Most likely this will also stimulate the search for newer and possibly better central initiators 25 of which Uprima 1 has become the first clinically useful example. The critical phase of acceptance is when the drug meets the patients it has been developed for. The original concepts of the value to the patient of rapid action that preserves spontaneity as it delivers efficacy is only poorly assessed in the dry numbers of regulatory based clinical trials. The complex array of factors that guide choice in men and their partners coping with ED in their selection of therapy will be self-evident in adoption rates. However, there is much more to be learned about this, and indeed any treatment for sexual dysfunction, in terms of impact on patients with particular needs and characteristics. Phase IV trials and clinical usage will generate more information in these areas.
Conclusions
Although Uprima 1 did not have to go through the initial steps of the chemical discovery phase (concept and chemical development), it has still passed through multiple and protracted trials even before reaching the phase III level in drug development. The evolution from apo to Uprima 2 still took over 10 y from the animal studies to a viable clinical product. Its' final success will be eventually measured by its' acceptance by the medical profession and, above all, the patients with whom the power to choose a therapy for ED rightly remains. 
